Lodo Therapeutics

New York, United States Founded: 2015 • Age: 11 yrs Acquired By Zymergen
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI

About Lodo Therapeutics

Lodo Therapeutics is a Healthcare company based in New York (United States) founded in 2015 by Sean Brady, and was acquired by Zymergen in May 2021. Developer novel therapeutics to treat resistant infectious diseases and cancers using AI. Lodo Therapeutics has raised $19.87 million across 1 funding round from investors including AbbVie, Lilly and ARE. The company has 24 employees. Lodo Therapeutics has completed 2 acquisitions, including Conifer Point and Hibiskus. Lodo Therapeutics offers products and services including AI Models, Data Generation, and Lab Automation. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is LODO THERAPEUTICS CORPORATION. Its competitors include Insmed, Affinivax and Symbiomix Therapeutics; 2 of its 3 listed competitors have raised funding.

Company details

Lodo Therapeutics was founded in 2015 and is based in New York, United States. Operations center on the biotech sector, where a metagenomics-driven platform is employed for discovering, biosynthesizing, and characterizing genetically encoded small molecules from microbial sources. Microbiome-derived pharmaceutical products are identified, with a focus on treatments for resistant infectious diseases, cancers, and tuberculosis.

  • Headquarters New York, United States
  • Employees 24
  • Founders Sean Brady
  • Stage Acquired
  • Sectors
    Healthcare
  • Website lodotherapeutics.com
  • Social LinkedIn
  • Acquired by Zymergen (May 2021)
  • Legal Name Lodo Therapeutics Corporation
Operational Areas
Key Metrics
  • Total Equity Funding
    $19.87M (USD)

    in 1 rounds

  • Latest Funding Round
    $19.87M (USD), Series A

    Jan 2017

  • Investors
    AbbVie

    & 13 more

  • Employee Count
    24
  • Investments & Acquisitions
  • Acquired by
    Zymergen

    (May 2021)

Products & Services of Lodo Therapeutics

Lodo Therapeutics offers a comprehensive portfolio of products and services, including AI Models, Data Generation, and Lab Automation.

AI Models
AI Tools

Provides fine-tuning for AI in biotechnology research

Data Generation
Data Services

Generates high-quality datasets for R&D applications

Lab Automation
Automation Tools

Offers hardware and software for efficient lab processes

Funding Insights of Lodo Therapeutics

Lodo Therapeutics has successfully raised a total of $19.87M through 1 strategic funding round. The most recent funding activity was a Series A round of $19.87 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $19.87M
  • Total Rounds 1
  • Last Round Series A β€” $19.87M
  • First Round $19.87M

    (Jan 2017)

  • Investors Count 13

All 1 funding rounds of Lodo Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2017$19.87MSeries A––
Valuation history

14 investors in total: 14 institutional.

Investors in Lodo Therapeutics

Lodo Therapeutics has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, Lilly and ARE.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on life science companies
1986archventure.comChicago, United States
Economic growth is supported via family-backed investments in New York.
1768pfnyc.orgNew York, United States
VC firm funding companies in the US
1981180degreecapital.comMontclair, United States
Venture capital services are offered for early-stage biotech companies.
acceleratorlsp.comSeattle, United States
Venture capital is focused on healthcare by Pfizer's investment arm.
pfizer.com/partnering/areas_of_interest/venture_investmentsNew York, United States
Biopharmaceutical research and drug development are conducted globally by AbbVie.
2012abbvie.comChicago, United States
Traditional pharmaceutical medicines are developed for multiple health fields.
1876lilly.comUnited States
jnjinnovation.com
Develops and manufactures APIs, finished dosage forms, and biologics.
2000wuxipharmatech.comShanghai, China
Charitable foundation investments on poverty reduction and healthcare
2000gatesfoundation.orgSeattle, United States
Premium access

Investor details for Lodo Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Lodo Therapeutics

13 people are tracked at Lodo Therapeutics (6 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 24.

NameRoleGroup
Sean Brady
Co-FounderLeadership
Subodh S. Deshmukh
Chief Development OfficerLeadership
Jay Flatley
Chairman & Acting CEOLeadership
Enakshi Singh
CFOLeadership
Lincoln Germain
Chief Commercial OfficerLeadership
Dmitriy Ryaboy
CTOLeadership
Sandi Peterson
Lead Independent DirectorBoard & advisors
Travis Murdoch
DirectorBoard & advisors
Christine Gorjanc
DirectorBoard & advisors
Steven Chu
DirectorBoard & advisors
Matt Ocko
DirectorBoard & advisors
Rohit Sharma
DirectorBoard & advisors
Devin Scannell
SVP, Drug DiscoveryTeam
Premium access

Complete people profiles for Lodo Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Lodo Therapeutics

Lodo Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Conifer Point and Hibiskus.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Small-molecule therapeutics for cancer are developed by Hibiskus.
hibiskusbio.comKalamazoo, United States2017Sep 2020β€’β€’β€’β€’
New drugs are developed using custom fragment-based design software.
coniferpoint.comDoylestown, United States2015Aug 2020β€’β€’β€’β€’
Premium access

Complete acquisition details for Lodo Therapeutics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Lodo Therapeutics

5 dated milestones of Lodo Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Lodo Therapeutics is founded.
  2. Funding First funding round of $19.9M.
  3. Acquisition Acquires Conifer Point.
  4. Acquisition Acquires Hibiskus.
  5. Exit Acquired by Zymergen.

Competitors of Lodo Therapeutics

Lodo Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Insmed, Affinivax and Symbiomix Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
insmed.com1999Bridgewater, United States912
Developer of small molecule inhibitors for rare lung diseases
affinivax.com2013Cambridge, United States$359.49M132
Technology-based conjugate vaccines against infectious diseases are developed.
symbiomix.com2012Newark, United States$66.55M
Late-stage biopharma antibiotics for gynecological infections are developed.
Premium access

Detailed competitors of Lodo Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Infectious Diseases

3 companies that operate in the same segment as Lodo Therapeutics (Infectious Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Developer of molecular diagnostic testing solutions
1996Sunnyvale, California, United StatesUSD 19.1 MUSD 87.11 M4,647
Therapeutics for drug-resistant bacterial infections are developed.
2013Cambridge, Massachusetts, United StatesUSD 114.7 MUSD 59.62 M32
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Lodo Therapeutics

Premium access

Complete news archive for Lodo Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Lodo Therapeutics

Lodo Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Lodo Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.

Lodo Therapeutics is a funded company, having raised a total of $19.87M across 1 funding round to date. The company's 1st funding round was a Series A of $19.87M, raised on Jan 2017.

Lodo Therapeutics has 24 employees.

Lodo Therapeutics was founded in 2015 and is based in New York, United States. Operations center on the biotech sector, where a metagenomics-driven platform is employed for discovering, biosynthesizing, and characterizing genetically encoded small molecules from microbial sources. Microbiome-derived pharmaceutical products are identified, with a focus on treatments for resistant infectious diseases, cancers, and tuberculosis.

Lodo Therapeutics's top competitors include Insmed, Affinivax and Symbiomix Therapeutics.

Lodo Therapeutics offers AI Models, Data Generation, and Lab Automation.

Lodo Therapeutics has made 2 acquisitions, including Conifer Point, and Hibiskus.

Lodo Therapeutics has 14 investors. Key investors include AbbVie, Lilly, ARE, New York State, and Zymergen.

Lodo Therapeutics operates through Lodo Therapeutics Corporation.

Yes. Lodo Therapeutics was acquired by Zymergen in May 2021.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available